Serum α- and γ-tocopherol concentrations and risk of advanced beta cell autoimmunity in children with HLA-conferred susceptibility to type 1 diabetes mellitus - Diabetologia

Vitamin E is a fat-soluble vitamin of plant origin consisting of eight structurally related compounds and is a classic free radical scavenging antioxidant [1]. The principal vitamers both in the diet and in human tissues are α- and γ-tocopherol [2]. Research has focused mainly on α-tocopherol because of its superior vitamin activity in rat fetal resorption assays [3] and prevalence in the human body [1]. However, γ-tocopherol provides different antioxidant activities [2], even exceeding those of α-tocopherol in some aspects [3, 4], and has anti-inflammatory properties beyond its antioxidant action [3]. γ-Tocopherol also seems to be a more predictive protective factor for certain types of cancer and myocardial infarction [1] than α-tocopherol.

Free radicals have been implicated in the aetiology of type 1 diabetes mellitus. Pancreatic islet cells are especially susceptible to the toxic effects of free radicals [5]. In insulitis leading to beta cell destruction, islet-infiltrating macrophages release free radicals, and also beta cell toxic cytokines and cytotoxic T cells may act via excessive formation of oxygen free radicals [6, 7]. Animal models of type 1 diabetes mellitus have indicated that vitamin E may have protective effects [5, 8–10].

Two epidemiological studies have been published on the associations of vitamin E with the risk of type 1 diabetes mellitus, both from Finland. The number of cases was small in both studies, but the results supported the hypothesis of vitamin E playing a protective role against diabetes. Serum α-tocopherol concentrations were inversely associated with diabetes in a case–control study nested within a 21 year follow-up of adult men [11]. In a cohort of initially non-diabetic siblings of children with diabetes, we found an inverse relationship of borderline significance between serum α-tocopherol concentrations and the risk of diabetes [12]. To the best of our knowledge, there are no epidemiological analyses of serum γ-tocopherol in this context.

In the present study, we assessed the associations of serum α- and γ-tocopherol concentrations with the risk of advanced beta cell autoimmunity in a birth cohort of children with HLA-conferred susceptibility to type 1 diabetes mellitus.

Participants

In the Type 1 Diabetes Prediction and Prevention (DIPP) Project, a prospective population-based cohort study [13], newborn infants from the areas of three university hospitals in Finland were screened for HLA-DQB1-conferred susceptibility to type 1 diabetes mellitus using samples of cord blood. Infants carrying increased genetic susceptibility (HLA-DQB1*02/0302 heterozygous and DQB1*0302/x-positive individuals, x standing for homozygosity or a neutral allele) were monitored for diabetes-associated autoantibodies, growth, viral infections and nutrition at 3–12 month intervals. The procedures were approved by the local Ethics Committees. The families signed informed written consent. The cases and control participants in the present analyses came from a cohort of the at-risk children born between 1 October 1996 and 1 July 2004 in Oulu University Hospital and between 20 October 1997 and 6 July 2004 in Tampere University Hospital (n = 5,787, 76% of the children invited).

Of the four type 1 diabetes-associated autoantibodies analysed, islet cell antibodies (ICA) were used as the primary screening tool for beta cell autoimmunity. When a child seroconverted to positivity for ICA for the first time, all the child’s preceding and subsequent samples were analysed for insulin autoantibodies (IAA), 65 kDa isoform of glutamic acid decarboxylase antibodies (GADA) and tyrosine phosphatase-related islet antigen 2 antibodies (IA-2A). For the present analyses, autoantibodies were followed until 30 September 2004. Among the 5,787 children, 119 (2.1%) were repeatedly positive for ICA plus at least one other antibody during the median follow-up time of 2.1 years (range 0.18–7.9 years) since birth. By 20 November 2004, 45 children (0.8%) had progressed to clinical type 1 diabetes mellitus at a median age of 3.1 years (range 1.0–6.4 years). Among these, 36 had been repeatedly positive for ICA plus at least one other autoantibody. However, six of the remaining nine children had had one or more autoantibodies in a single sample before or at the time of diagnosis. The three persistently seronegative children had had the last blood sample drawn 1.9, 3.3 and 5.2 years before the diagnosis of diabetes, respectively. Therefore we decided to include clinical type 1 diabetes mellitus in the autoantibody endpoint. This resulted in 128 children (2.2% of all children) with the composite endpoint of clinical diabetes or being repeatedly positive for ICA plus at least one other antibody, i.e. having advanced beta cell autoimmunity, which term will be used throughout the text for the endpoint.

The study was designed as a nested case–control study. For each case, two matched control participants were selected. First, all possible control participants who fulfilled the matching criteria were selected from the entire DIPP Nutrition cohort. The matching criteria included birth date within 3 months, the same sex, the same hospital of birth, the same genotype (HLA-DQB1*02/0302 heterozygous, defined as high risk or DQB1*0302/x, defined as moderate risk), and the control participants must not come from the same family as the case. The control participants could come from the same family. The control participant children must have been observed at the visit when the case turns out to be a case and they must have been seronegative and non-diabetic up to that point. From the series of all possible control participant children fulfilling the matching criteria, two control participants were randomly selected. If the selected control participants did not have a blood sample for vitamin E analysis, extra control participants were randomly selected. The control participants of each case were selected totally independently, so that the same individual could be a control for more than one case, and an individual who was already a control for one or more cases could him- or herself become a case at a later time point.

A serum sample for vitamin E analyses, separate from the sample drawn for the autoantibody follow-up, was collected from all the children in the cohort at the age of 1 year and thereafter at 12 month intervals. For each case–control group, all the repeated serum samples up to the age of seroconversion of the case were analysed. There were 20 cases with no vitamin E samples drawn until the age of seroconversion. These cases and their matched control participants were dropped from the analyses.

Genetic methods

The HLA-DQB1 alleles were analysed as described earlier [14]. In brief, a part of the second exon of the HLA-DQB1 gene was amplified using a primer pair with a biotinylated 3′ primer. The biotinylated PCR products were then transferred to streptavidin-coated microtitration plates, denatured and hybridised with sequence-specific probes labelled with lanthanide chelates: europium, terbium or samarium. Two hybridisation mixtures were used, one containing probes hybridising with DQB1*0602 and *0603, DQB1*0603 and *0604 and a consensus sequence, and the other containing probes specific to the DQB1*02, *0301 and *0302 alleles. After appropriate incubations and washings, the specific hybridisation products were detected using three-colour time-resolved fluorescence of the lanthanide chelates.

Immunological methods

The detection of type 1 diabetes-associated autoantibodies has been described previously [15]. In brief, ICA were quantified by a standard indirect immunofluorescence method on sections of frozen human pancreas from a blood group O donor [16]. Serum IAA were quantified with a microassay [17, 18] and GADA and IA-2A with specific radiobinding assays [19, 20]. Transplacentally transferred autoantibodies, which were present in cord blood and thereafter disappeared from the child’s serum [21], were excluded from the analyses.

Determination of vitamin E and cholesterol

Non-fasting blood samples for vitamin E and cholesterol analyses were collected by venipuncture. Samples were protected from light during processing. They were kept at room temperature for 30–60 min to clot. After centrifugation, a sample of at least 1 ml serum from 1-year-old children and 2 ml from age 2 years onwards was separated and stored at −70°C prior to analyses. Samples were transported on dry ice to the National Public Health Institute for the analyses. Serum α- and γ-tocopherol concentrations were measured at the Biomarker Laboratory with a micromethod on 50 μl aliquots with reversed-phase HPLC with detection by fluorescence at 292/324 nm [22]. The precision between series was 5.0 CV% for α-tocopherol and 6.7 CV% for γ-tocopherol. Serum cholesterol concentrations were analysed manually at the Laboratory of Analytical Biochemistry by an Olli-C photometer (Thermo Fisher Scientific Oy, Vantaa, Finland) using an enzymatic (CHOD-PAP) method. The laboratory personnel were unaware of the case–control status of the samples. Each case–control group was analysed in the same batch. Within each case–control group, the samples were in random order in relation to the case–control status.

Collection of background characteristics

Information on parental age and education was registered by a structured questionnaire after the delivery. Information on gestational age, number of earlier deliveries of the mother (parity) and maternal smoking during pregnancy was received from the Medical Birth Registries of the Oulu and Tampere University Hospitals.

Statistical methods

The study endpoint is interval-censored. Therefore, a conditional likelihood analysis of a logistic regression model was used within the nested case–control design to estimate potential associations between seroconversion and serum α-tocopherol and γ-tocopherol levels. The explanatory variables were treated as both continuous and categorical after aggregation into low (values less than the 25th percentile), intermediate (within the interquartile range) and high (above the 75th percentile) values. As more than 40% of the seroconversions took place before the second year of age, the first-year serum values were employed in the model. A model that allowed an interaction with the time of seroconversion was fitted as well. Moreover, the effect of an average category of individual α-tocopherol and γ-tocopherol concentrations over time on the response was estimated. Adjusted multiple logistic regression models included serum cholesterol and background characteristics (education of the mother and the father, maternal age, duration of gestation, diabetes of a first-degree relative, number of earlier deliveries, maternal smoking during pregnancy) in addition to α- or γ-tocopherol concentrations. The analyses were conducted on the observed data and, to reduce potential bias associated with missing explanatory variables and to allow individuals with incomplete sets of explanatory variables to be included, multiple imputation was used. The sequential imputation regression method [23] as implemented in the IVEware software was used to generate five sets of imputed missing values and the final estimates and their SEs were calculated according to Rubin’s rules [24]. α-Tocopherol and γ-tocopherol concentrations were imputed for 11 cases and 17 control participants. SAS version 9.1.3 (SAS Institute, Cary, NC, USA) was used in the analyses. Full details of the imputation models used are available from the authors on request.

The distributions of sex, delivery hospital and genetic risk group, which were used as matching criteria, were identical for cases and control participants (Table 1). Diabetes in a first-degree relative was more common among cases than control participants. The mothers of the cases belonged to the highest age and education categories more frequently than the mothers of control participant children. There were one twin pair and three sibling pairs among the study population. There were no siblings within the same case–control group. Neither child of the twin pair was a case.

The age-specific mean concentrations of control participants ranged from 15.5 to 18.5 μmol/l for α-tocopherol, from 1.18 to 2.09 μmol/l for γ-tocopherol and from 4.39 to 4.88 mmol/l for cholesterol (Fig. 1). Concentrations of α-tocopherol and cholesterol were stable across the age range of 1–6 years, while the γ-tocopherol concentration at the age of 1 year tended to be lower than in the older age groups.

Serum α-tocopherol (μmol/l) (a), γ-tocopherol (μmol/l) (b) and cholesterol (mmol/l) (c) concentrations of control participants (triangles, mean values) and cases (circles, mean values) by age groups. The central bar in the boxplots represents the median concentration, the box represents the interquartile range (IQR), and the whiskers represent the smallest and largest non-outlier concentrations. The asterisks represent outliers, i.e. observations that lie more than 1.5×IQR lower than the first quartile or 1.5 × IQR higher than the third quartile

Full size image

Serum α- or γ-tocopherol concentrations were not significantly associated with the risk of advanced beta cell autoimmunity (Table 2). α-Tocopherol or γ-tocopherol concentrations at the age of 1 year were not significant predictors of seroconversion, irrespective of whether they were analysed as continuous or categorical quartile variables. Neither were the average levels of α- or γ-tocopherol in all samples up to the time of seroconversion associated with the risk. Multiple imputation of missing values or adjustment for serum cholesterol concentration, education of the mother and the father, maternal age, duration of gestation, diabetes in a first-degree relative, number of earlier deliveries and maternal smoking during pregnancy did not change the magnitude of the associations or improve the precision of the results.

However, there was an interaction between high vs intermediate values of γ-tocopherol at the age of 1 year and the time of seroconversion (Fig. 2), possibly indicating an inverse association between γ-tocopherol and the risk of advanced beta cell autoimmunity at a young age (p = 0.024). α-Tocopherol concentration at the age of 1 year analysed as a continuous variable showed a borderline interaction with the time of seroconversion (p = 0.094).

Odds ratios (solid line) and 95% CIs (dotted lines) of developing advanced beta cell autoimmunity for high vs intermediate γ-tocopherol concentrations in the first-year sample, presented by age

Full size image

In the present case–control study nested within a birth cohort of children with HLA-conferred susceptibility to type 1 diabetes mellitus, serum α- or γ-tocopherol concentrations were not significantly associated with the risk of advanced beta cell autoimmunity. Potential confounding by several sociodemographic and clinical variables was controlled for by matching or adding them into the statistical models as covariates. The only significant finding was an interaction of high γ-tocopherol concentrations at the age of 1 year with the time to seroconversion. In the light of these results, a substantial protective effect of high α- or γ-tocopherol concentrations against pre-type 1 diabetes in young children seems unlikely.

In a small cross-sectional study, plasma α-tocopherol concentrations of individuals with type 1 diabetes-associated autoantibodies tended to be slightly lower than those of unaffected control participants, but the difference was not significant [25]. In two earlier cohort studies, however, a significant [11] or borderline [12] inverse association between serum α-tocopherol concentrations and type 1 diabetes mellitus was observed. The number of diabetic cases in these studies ranged from 16 to 26. The serum samples were stored at −20°C for several years, which may cause a substantial decrease in α-tocopherol concentrations [26]; at −70°C, tocopherols have been shown to be stable for at least 4 years of storage [27]. Indeed, the mean α-tocopherol concentrations were higher in the samples of the present study stored at −70°C than in the earlier studies. The mean concentration of control participants was 14.9 μmol/l in one study [11], 9.22 μmol/l in another [12] and 15.5–18.5 μmol/l in the present study. Because of the approximately fourfold number of cases and better preserved serum samples, we consider the present results of no association more reliable than the earlier findings of an inverse association, even if one would have expected that the error caused by the degradation of α-tocopherol during storage would have biased the association towards null. However, the rate of decline of vitamin E has been shown to vary considerably between individuals [26]; thus, one can not rule out the possibility that some other components in serum influence the individual rate of decrease in α-tocopherol during storage, and are themselves associated with the risk of type 1 diabetes, causing the observed associations in the two earlier studies [12].

On the other hand, the discrepant results of the earlier cohort studies and the present study may result from differences in the study population and the endpoint variable used. In other studies [11, 12], the endpoint was clinical type 1 diabetes mellitus, while in the present study and in another [25] the outcome was beta cell autoimmunity, representing a prediabetic phase. It is possible that high vitamin E concentrations protect against the development of prediabetes to overt diabetes and are not as strongly associated with the emergence of autoantibodies in earlier phases of the disease process. Compatible with this view, we found a marginally significant association between serum α-tocopherol and risk of clinical diabetes in a cohort of seropositive children [12]. Also, the effect of α-tocopherol could differ by age group. In the present data, the study individuals were younger than in the earlier studies. In other studies, the average age of the cases was 28 years [11], 13.1 years [12] and 13.8 years [25], and 2.5 years in the present study.

There may be also methodological reasons for the lack of association between serum α-tocopherol concentrations and prediabetes in the present study. For more than 40% of the cases there was only one vitamin E sample available. It has been shown that day-to-day intra-individual variation in plasma α-tocopherol may cause large attenuations in the observed associations with any other factors, when a single measurement per person is used [28]. Furthermore, the validity of serum or plasma α-tocopherol as an indicator of dietary intake is uncertain. The correlations between the concentrations and intakes of α-tocopherol or vitamin E have been weak [29, 30], especially among non-users of vitamin E supplements [31, 32]. In children, most of the reported correlations have been non-significant [33–36], while in one study [37] a moderate correlation was found. However, the weak correlations could result from problems associated with the dietary assessment methods [38].

To our knowledge, this is the first epidemiological report on the association of blood γ-tocopherol concentrations and type 1 diabetes mellitus. We observed an interaction of high γ-tocopherol concentrations at the age of 1 year with the time to seroconversion. Because most of the seroconversions took place at an early age, it was not possible to separate the effect of age from the effect of time from the γ-tocopherol measurement to the seroconversion. Thus, high γ-tocopherol concentrations could be protective in the youngest children only, or they might offer only short-term protection against advanced beta cell autoimmunity. These data are compatible with the interpretation that high γ-tocopherol concentrations at the age of 1 year are associated with an increased risk of seroconversion at a later age; for biological reasons, this interpretation seems less likely. It is interesting to note that γ-tocopherol concentrations tended to be lower at the age of 1 year, co-occurring with the age of a possible protective effect provided by high concentrations.

In the light of these preliminary findings, γ-tocopherol provides an interesting target for future research. To confirm or rule out the possible inverse association of serum vitamin E with type 1 diabetes mellitus, studies with multiple vitamin E measurements per individual and still larger number of cases, preferably with clinical disease, are needed. Because of the uncertain validity of serum tocopherol concentrations as an indicator of dietary intake, studies on the association of dietary vitamin E intake with the development of type 1 diabetes mellitus are particularly interesting.

Authors

1. L. Uusitalo

   You can also search for this author inPubMed Google Scholar

2. J. Nevalainen

   You can also search for this author inPubMed Google Scholar

3. S. Niinistö

   You can also search for this author inPubMed Google Scholar

4. G. Alfthan

   You can also search for this author inPubMed Google Scholar

5. J. Sundvall

   You can also search for this author inPubMed Google Scholar

6. T. Korhonen

   You can also search for this author inPubMed Google Scholar

7. M. G. Kenward

   You can also search for this author inPubMed Google Scholar

8. H. Oja

   You can also search for this author inPubMed Google Scholar

9. R. Veijola

   You can also search for this author inPubMed Google Scholar

10. O. Simell

    You can also search for this author inPubMed Google Scholar

11. J. Ilonen

    You can also search for this author inPubMed Google Scholar

12. M. Knip

    You can also search for this author inPubMed Google Scholar

13. S. M. Virtanen

    You can also search for this author inPubMed Google Scholar